Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | CTNNB1 | P35222 | 9/20 | 0.64 |
| ▸ | WNT3A | P56704 | 6/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1443215 | 0.98 | ATM (0.68) | ATMTSHRHPGDPKMCTNNB1 | |
| Hydrochloric Acid SCHEMBL4195016 | 0.98 | ATM (0.68) | ATMTSHRHPGDPKMCTNNB1 | |
| SCHEMBL2843731 | 0.89 | CTNNB1 (0.64) | ATMHPGDCTNNB1WNT3AKDM4E | |
| Hydrochloric Acid SCHEMBL6818531 | 0.88 | CTNNB1 (0.62) | ATMHPGDCTNNB1WNT3AKDM4E | |
| SCHEMBL653025 | 0.85 | PKM (0.87) | ATMTSHRHPGDPKMCTNNB1 | |
| SCHEMBL4831672 | 0.84 | ATM (0.72) | ATMTSHRHPGDPKMCTNNB1 | |
| SCHEMBL1535157 | 0.84 | ATM (0.72) | ATMTSHRHPGDPKMCTNNB1 | |
| SCHEMBL26728280 | 0.83 | ATM (0.71) | ATMTSHRHPGDPKMCTNNB1 | |
| SCHEMBL5808134 | 0.82 | ATM (0.70) | ATMTSHRHPGDPKMCTNNB1 | |
| SCHEMBL13785039 | 0.82 | ATM (0.70) | ATMTSHRHPGDPKMCTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020020365-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE ELIGLUSTAT | 中国医学科学院药物研究所 | 2020-01-30 | — | — | WO | disclosed |
| WO-2018193090-A2 | PROCESS FOR PREPARATION OF ELIGLUSTAT HEMITARTRATE AND INTERMEDIATES THEREOF | AMNEAL PHARMACEUTICALS COMPANY GMBH (CH) | 2018-10-25 | — | — | WO | disclosed |
| WO-2010039911-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-1636217-B1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-09-03 | — | — | EP | disclosed |
| EP-1450796-B1 | BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| US-7122545-B2 | Imidazo-benzothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1636217-A1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| US-6890949-B1 | Amino ceramide-like compounds and therapeutic methods of use | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2004101558-A1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
| US-20040229862-A1 | Imidazo-benzothiazoles | F. HOFFMAN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | disclosed |
| EP-1384719-A1 | Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections | The Regents of The University of Michigan (US) | 2004-01-28 | — | — | EP | disclosed |
| US-6596718-B1 | A compound of formula I has a good affinity to the A2A receptor and is useful for the treatment of diseases mediated by this receptor. | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| EP-1196406-A1 | AMINO CERAMIDE-LIKE COMPOUNDS AND THERAPEUTIC METHODS OF USE | The Regents of the University of Michigan (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001004108-A1 | AMINO CERAMIDE-LIKE COMPOUNDS AND THERAPEUTIC METHODS OF USE | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229862-A1 | Imidazo-benzothiazoles | ADORA1, ADORA3, ADORA2A | ATM 3239/4885TSHR 100/4885HPGD 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.